Hereditary Angioedema
Median hereditary angioedema attack rates fall to zero for children with berotralstat
SAN DIEGO — Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a median of zero after the first month and at 12 months, according to a poster presented here.
Top in allergy/asthma: Passing of Marcus Maurer, MD; briquilimab for chronic urticaria
The allergy and immunology community mourns the loss of Marcus Maurer, MD, executive director of the Institute of Allergology at Charité University Medicine in Berlin, who is remembered for his excellent teaching and scientific achievements.
Lanadelumab increases attack-free rates in hereditary angioedema patients
Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
Top 10 skin disorder stories of 2024
The year 2024 was important for skin disorders with many innovations and breakthroughs.
Patients with hereditary angioedema down-titrate lanadelumab, maintain symptom control
BOSTON — Patients with hereditary angioedema may down-titrate lanadelumab treatment while exhibiting symptom control, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Patients with hereditary angioedema prefer daily oral treatment over periodic injections
BOSTON — Patients with hereditary angioedema preferred daily pills over periodic subcutaneous injections for prophylactic care, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
FDA accepts new drug application for donidalorsen
The FDA accepted a new drug application for review of donidalorsen, a prophylactic RNA-targeting drug used to prevent hereditary angioedema attacks in patients aged 12 years and older, according to a press release from Ionis.
Hereditary angioedema controlled in 4 weeks with deucrictibant
BOSTON — Patients with hereditary angioedema who used deucrictibant for 12 weeks experienced improved symptom control, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Hereditary angioedema attack rates fall with berotralstat
BOSTON — Patients with hereditary angioedema saw significant reductions in attacks for 18 months after beginning berotralstat, according to two posters at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Deucrictibant shows long-term efficacy, safety in treatment of hereditary angioedema
Deucrictibant was well tolerated in daily 40 mg doses and showed no new safety signals among patients with hereditary angioedema, according to a poster presented at Bradykinin Symposium 2024 in Berlin.